Article Text

PDF
Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety
  1. Antonio José Villatoro1,2,
  2. Manuel Hermida-Prieto3,
  3. Viviana Fernández1,2,
  4. Fernando Fariñas2,
  5. Cristina Alcoholado1,4,
  6. M Isabel Rodríguez-García3,
  7. Luis Mariñas-Pardo3 and
  8. José Becerra1,4,5
  1. 1Laboratory of Bioengineering and Tissue Regeneration (LABRET), Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain
  2. 2Cellular Therapy Unit, Instituto de Inmunología Clínica y Terapia Celular (IMMUNESTEM), Málaga, Spain
  3. 3Research and Development, Centauri Biotech SL, Arteixo, Spain
  4. 4Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
  5. 5Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain
  1. E-mail for correspondence; luis.marinas{at}centauribiotech.com

Abstract

Canine atopic dermatitis (AD) is a common skin disease with a 10–15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. The aim of this study was to evaluate the therapeutic efficacy and safety of allogeneic canine adipose MSCs (cAd-MSCs) in dogs with refractory AD. Twenty-six dogs, suffering from AD for at least 12 months, not responding to conventional therapy, received an intravenous dose of 1.5×106 cAd-MSCs/kg bodyweight. Clinical signs, haematological and biochemistry profiles, and AD severity were assessed in a six-month follow-up using a validated scoring system (Canine Atopic Dermatitis Extent and Severity Index, version 4 (CADESI-04)). The degree of pruritus was quantified using a validated visual analogue scale, and also owner’s global assessment of treatment efficacy. Twenty-two animals completed the study. Pruritus and CADESI-04 scores decreased significantly after one week or month of treatment, respectively, and remained stable for six months. Owner’s global assessment score was 2.15±1.15 for all the animals in the study. In conclusion, systemic administration of allogeneic cAd-MSCs appeared to be a simple therapy with positive outcome in the remission of clinical signs for AD refractory to conventional medications, for at least six months and with no adverse events.

  • canine atopic dermatitis
  • cell therapy
  • mesenchymal stem cells
  • canine medicine
  • refractory autoimmune diseases

Statistics from Altmetric.com

Footnotes

  • AJV and MH-P contributed equally.

  • Funding This work was partially supported by the Spanish Network on Cell Therapy (Red TerCel, RD16/0011/0022), BIO2015-66266-R (MINECO) and P11-CVI-7245 (Junta de Andalucia). CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program and CIBER Actions, and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund.

  • Competing interests None declared.

  • Ethics approval All animal procedures and protocols were conducted by licensed veterinary surgeons and comply with both national and European legislation (Spanish Royal Decree RD1201/2005 and EU Directive 86/609/CEE, as modified by 2003/65/CE, respectively) for the protection of animals used for research and experimentation and for other scientific purposes. Likewise, the Institutional Animal Care and Use Committee, Andalusian Centre, approved the protocols for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.